Nab-paclitaxel + Cisplatin + Fluorouracil

The combination of nab-paclitaxel, cisplatin, and fluorouracil (often abbreviated as APF) is an induction chemotherapy regimen primarily used in the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC). ## Composition and Mechanism This regimen combines three distinct anticancer agents: 1. **Nab-paclitaxel** (albumin-bound paclitaxel): A novel taxane formulation that uses albumin nanoparticles to improve drug delivery to tumor tissue. This formulation may enhance the therapeutic index compared to conventional taxanes like docetaxel. 2. **Cisplatin**: A platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription. 3. **Fluorouracil (5-FU)**: An antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. ## Clinical Applications The APF regimen has been studied primarily as induction chemotherapy followed by concurrent chemoradiation therapy (CRT) in: - Locally advanced head and neck squamous cell carcinoma (HNSCC) - Esophageal squamous cell carcinoma (ESCC) - Nasopharyngeal carcinoma (as part of nab-TPC regimen with capecitabine) ## Dosing Regimen Based on phase I/II trials, the recommended dosing for APF induction chemotherapy is: - Nab-paclitaxel: 100 mg/m² on days 1, 8, and 15 - Cisplatin: 75 mg/m² on day 1 - 5-Fluorouracil: 750-1000 mg/m² continuous infusion daily on days 1-3 or 1-4 This regimen is typically administered in 3-week cycles for 2-3 cycles before proceeding to definitive therapy. ## Efficacy Clinical trials have demonstrated promising efficacy with the APF regimen: - In HNSCC: A phase II trial showed favorable two-year disease-specific survival, progression-free survival, and overall survival with a low relapse rate. - In ESCC: Studies have shown significant tumor downstaging and pathologic complete response rates. - Response rates: Complete or partial responses at the primary tumor site have been observed in a high percentage of patients, allowing for subsequent definitive therapy. ## Safety Profile Common adverse events associated with APF include: - Hematologic toxicities: Neutropenia, anemia, thrombocytopenia, and lymphopenia - Non-hematologic toxicities: Fatigue, hyponatremia, and mucositis The regimen appears to have a manageable toxicity profile, with grade 3-4 adverse events occurring at acceptable rates for an intensive induction chemotherapy regimen. ## Current Development Status The APF regimen has been evaluated in multiple phase I and II clinical trials, with ongoing investigation into its role in sequential therapy approaches for various squamous cell carcinomas. It represents a promising alternative to other induction chemotherapy regimens, particularly in settings where improved drug delivery to tumor tissue may be beneficial.